Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert B Jenkins

Showing results (101-110 of 269) with videos related to

Pageof 27
Sort By:
American Journal of Clinical Pathology|July 28, 2010
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assayWeidong Huang, Monica Reinholz, Jodi Weidler, et al.
Cancer Research|April 15, 2010
Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomasAaron M Bender, Lara S Collier, Fausto J Rodriguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivorsEric C Burton, Kathleen R Lamborn, Peter Forsyth, et al.
American Journal of Clinical Pathology|May 4, 2021
Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization ResultsKatherine B Geiersbach, Daniel R Sill, Kristina M Del Rosario, et al.
International Journal of Radiation Oncology, Biology, Physics|December 26, 2006
Central neurocytoma: management recommendations based on a 35-year experienceJames L Leenstra, Fausto J Rodriguez, Christina M Frechette, et al.
Cancer Research|September 24, 2009
Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromesDavid P Steensma, Jessemy D Neiger, Julie C Porcher, et al.
Journal of Neuro-Oncology|June 20, 2015
Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131Michael A Vogelbaum, Chen Hu, David M Peereboom, et al.
Neuro-Oncology|September 8, 2020
Development of a gene expression-based prognostic signature for IDH wild-type glioblastomaRadia M Johnson, Heidi S Phillips, Carlos Bais, et al.
BJU International|January 21, 2017
Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortalityKathryn L Pellegrini, Martin G Sanda, Dattatraya Patil, et al.
The Journal of Molecular Diagnostics : JMD|December 20, 2025
Development and Clinical Validation of OncCNV: A Pipeline for Comprehensive Genome-Wide Analysis of Oncogene Amplifications, Homozygous Deletions, and Biallelic Inactivation of Tumor Suppressor Genes Using the TruSight Oncology 500 KitStephanie A Smoley, Gopinath Sivasankaran, Mallika Gandham, et al.
Pageof 27

Showing results (101-110 of 269) with videos related to

Sort By:
Pageof 27
American Journal of Clinical Pathology|July 28, 2010
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assayWeidong Huang, Monica Reinholz, Jodi Weidler, et al.
Cancer Research|April 15, 2010
Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomasAaron M Bender, Lara S Collier, Fausto J Rodriguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivorsEric C Burton, Kathleen R Lamborn, Peter Forsyth, et al.
American Journal of Clinical Pathology|May 4, 2021
Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization ResultsKatherine B Geiersbach, Daniel R Sill, Kristina M Del Rosario, et al.
International Journal of Radiation Oncology, Biology, Physics|December 26, 2006
Central neurocytoma: management recommendations based on a 35-year experienceJames L Leenstra, Fausto J Rodriguez, Christina M Frechette, et al.
Cancer Research|September 24, 2009
Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromesDavid P Steensma, Jessemy D Neiger, Julie C Porcher, et al.
Journal of Neuro-Oncology|June 20, 2015
Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131Michael A Vogelbaum, Chen Hu, David M Peereboom, et al.
Neuro-Oncology|September 8, 2020
Development of a gene expression-based prognostic signature for IDH wild-type glioblastomaRadia M Johnson, Heidi S Phillips, Carlos Bais, et al.
BJU International|January 21, 2017
Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortalityKathryn L Pellegrini, Martin G Sanda, Dattatraya Patil, et al.
The Journal of Molecular Diagnostics : JMD|December 20, 2025
Development and Clinical Validation of OncCNV: A Pipeline for Comprehensive Genome-Wide Analysis of Oncogene Amplifications, Homozygous Deletions, and Biallelic Inactivation of Tumor Suppressor Genes Using the TruSight Oncology 500 KitStephanie A Smoley, Gopinath Sivasankaran, Mallika Gandham, et al.
Pageof 27